论文部分内容阅读
目的探讨急性冠脉综合征(ACS)患者厄贝沙坦治疗前后血巨噬细胞炎性蛋白1α(MIP-1α)及血栓调节蛋白(TM)水平的变化及临床意义。方法采用ELISA法测定52例健康对照者,86例ACS患者(随机分常规治疗40例和厄贝沙坦治疗46例)治疗前及治疗8周后血MIP-1α、TM含量。结果 ACS组治疗前血MIP-1α、TM水平明显高于对照组(P<0.05),治疗后明显下降(P<0.05),且厄贝沙坦组下降更明显(P<0.05)。结论 ACS的发生与MIP-1α、TM有关,厄贝沙坦可降低血MIP-1α、TM水平,并在抑制动脉粥样病变的炎症反应,保护血管内皮方面有一定作用。
Objective To investigate the changes and clinical significance of blood levels of macrophage inflammatory protein-1α (MIP-1α) and thrombomodulin (TM) in patients with acute coronary syndrome (ACS) before and after irbesartan treatment. Methods Serum levels of MIP-1α and TM in 52 healthy controls and 86 ACS patients (40 randomly assigned and 46 irbesartan treated) were measured by ELISA. Results The serum levels of MIP-1α and TM in ACS group were significantly higher than those in control group (P <0.05), but decreased significantly after treatment (P <0.05). Conclusion The occurrence of ACS is related to MIP-1α and TM. Irbesartan can reduce the levels of MIP-1α and TM in blood and play an important role in inhibiting the inflammatory reaction of atherosclerosis and protecting the vascular endothelium.